Results of leflunomide treatment of psoriatic arthritis

Terapevticheskii Arkhiv

Volumn 79, Issue 8, 2007, Pages 22-28

  Pchelintseva, A O ^a   Korotaeva, T V ^a   Godzenko, A A ^a   Korsakova, Yu L ^a   Stanislav, M L ^a   Denisov, L N ^a  

^a NONE

Author keywords

ACR 20; DLQI; HAQ; Leflunomide; PASI; PsARC; Psoriatic arthritis

Indexed keywords

IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; LEFLUNOMIDE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL; PSORIATIC ARTHRITIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTHRITIS, PSORIATIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 35148828193     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Moll J. M. H., Wright V. Psoriatic arthritis. Semin. Arthr. Rheum. 1973; 3 (1): 55-78.
2. Shbeeb M., Uramoto K. M., Gibson L. E. et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J. Rheumatol. 2000; 27: 1247-1250.
3. Alenius G. M., Stenberg B., Stenlund H. et al. Inflammatory joint manifestations are prevalent in psoriasis. J. Rheumatol. 2002; 29: 2577-2582.
4. Consilium Medicum 2005; 7(3): 181-188.
5. Rahman P., Nguyen E., Cheung C. et al. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J. Rheumatol. 2001; 28: 1041-1044.
6. Sokoll K. B., Helliwell P. S. Comparison of disability and quality of life in rheumatoid arthritis and psoriatic arthritis. J. Rheumatol. 2001; 28: 1842-1846.
7. Kane D., Stafford L., Bresnihan B., FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003; 42: 1460-1468.
8. Torre-Alonso J. C., Rodriguez Perez A. et al. Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. 1991; 30: 245-250.
9. Gladman D. D., Stafford-Brady F., Chang C. H. et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J. Rheumatol. 1990; 17: 809-812.
10. Gladman D. D., Farevell V. T. Progression in psoriatic arthritis: role of time varying clinical indicators. J. Rheumatol. 1999; 26: 2409-2413.
11. Queiro-Silva R., Torre-Alonso J. C., Tinture-Eguren T., Lopez-Lagunas I. A poliarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann. Rheum. Dis. 2003; 62: 68-70.
12. Gladman D. D., Blake R., Brubacher B., Farewell V. T. Chloroquine therapy in psoriatic arthritis. J. Rheumatol. 1992. 19: 1724-1726.
13. Mader R., Gladman D. D., Long J. et al. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin. Invest. Med. 1995; 18: 139-143.
14. Abu-Shakra M., Gladman D. D., Thorne J. C. et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatol. 1995; 22: 241-245.
15. Willkens R. F., Williams H. J., Ward J. R. et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthr. and Rheum. 1984; 27: 376-381.
16. Palit J., Hill J., Capell H. A. et al. A multicentre double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br. J. Rheumatol. 1990; 29: 280-283.
17. Salvarani C., Macchioni P., Boiardi L. et al. Low dose cyclosporin A in psoriatic arthritis: Relation between soluble interleukin 2 receptors and response to therapy. J. Rheumatol. 1992; 19: 74-79.
18. Black R. L., O'Brien W. M., Van Scott E. J. et al. Methotrexate therapy in psoriatic arthritis: double blind study of 21 patients. J. A. M. A. 1964; 189: 743-747.
19. Gupta A. K., Grober J. S., Hamilton T. A. et al. Sulfasalasine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J. Rheumatol. 1995; 22: 894-898.
20. Farr M., Kitas G. D., Waterhouse L. et al. Sulfasalasine in psoriatic arthritis: a double-blind, placebo-controlled study. Br. J. Rheumatol. 1990; 29: 1427-1434.
21. Russian source
22. Mease P. J., Antoni C. E. Psoriatic arthritis treatment: biological response modifiers. Ann. Rheum. Dis. 2005; 64 (suppl. II): ii78-ii82.
23. Fox R. I. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol. 1998; 25 (suppl. 53): 20-26.
24. Breedveld F. C., Dayer J.-M. Leflunomide-mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 2000; 59: 841-849.
25. Lacraz S., Isler P., Vey E. et al. Direct contact between T-lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. 1994; 269: 22027-22033.
26. Kraan M. C., Reece R. J., Barg E. C. et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthr. and Rheum. 2000; 43: 1820-1830.
27. Chen F., Castranova V., Shi X., Demers L. M. New insights into the role of nucleolar factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 1999; 45: 7-17.
28. Cutolo M., Sulli A., Ghiorzo P. et al. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann. Rheum. Dis. 2003; 62: 297-302.
29. Siemasko K. F., Chong A. S. F., Williams J. W. et al. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 1996; 61 (4): 635-642.
30. Russian source
31. Mladenovic V., Domljan Z., Rozman B. et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthr. and Rheum. 1995; 38: 1595-1603.
32. Strand V., Cohen S., Schiff M. et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. 1999; 159: 2542-2550.
33. Smolen J. S., Kalden J. R., Scott D. L. et al. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial. Lancet 1999; 353: 259-266.
34. Emery P., Breedveld F. C., Lemmel E. M. et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655-665.
35. Scott D. L., Smolen J. S., Kalden J. R. et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow-up of a double-blind, placebo controlled trial versus sulfasalazine. Ann. Rheum. Dis. 2001; 60: 913-923.
36. Russian source
37. Russian source
38. Scarpa R., Manguso F., Orient A. et al. Leflunomide in psoriatic polyarthritis. An Italian pilot study. Arthr. and Rheum. 2001; 44 (9, suppl.): S92.
39. Liang G. C., Barr W. G. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J. Clin. Rheum. 2001; 6: 366-370.
40. Liang G. C., Barr W. G. Long-term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthr. and Rheum. 2001; 44 (9, suppl.): S121.
41. Kaltwasser J. P., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthr. and Rheum. 2004; 50 (6): 1939-1950.
42. Fries J. F., Spitz P., Kraines R. G. et al. Measurement of patient outcome in arthritis. Arthr. and Rheum. 1980; 23: 137-145.
43. Bruce B., Fries J. F. The Health Assessment Questionnaire (HAQ). Clin. Exp. Rheumatol. 2005; 23 (suppl. 39): S14-S18.
44. Mease P. J., Ganguly R., Wanke L. et al. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann. Rheum. Dis. 2004; 63 (suppl. 1): 391.
45. Fredriksson T., Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatological (Basel) 1978; 157: 238-244.
46. Carlin C. S., Feldman S. R., Krueger J. G. et al. A 50% reduction in the Psoriasis Area and Severity Score (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol. 2004; 50: 859-866.
47. Finlay A. Y., Rhan G. K. Dermatology Life Quality Index (DL-QI) - a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 1994; 19: 210-216.
48. Mazzotti E., Picardi A., Sampogna F. et al. IDI Multipurpose Psoriasis Research on Vital Experiences (IM-PROVE) Study Group. Sensitivity of the dermatology life quality index to clinical change in patients with psoriasis. Br. J. Dermatol. 2003; 149: 318-322.
49. Clegg D. O., Reda D. J., Mejias E. et al. Comparison of sulfasalasine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs cooperative study. Arthr. and Rheum. 1996; 39: 2013-2020.
50. Mease P. J., Goffe B. S., Metz J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000; 356: 385-390.